BIOMARK DIAGNOSTIC

CSE

BUX

Biomark Diagnostics Inc. is an analytical, bioanalytical and drug metabolism and pharmacokinetic (DM/PK) contract research organization (CRO) servicing pharmaceutical and biotechnology companies in discovery, preclinical and clinical programs supporting investigational new drug (IND) and new drug application (NDA)-enabling studies. The Company is engaged in the cancer diagnostics using metabolites. The Company's metabolomics-based diagnostic assay allows cancer detection. The assay consists of screening for the acetylated form of a drug (Amantadine) given to patients prior to measurement through liquid chromatography mass spectrometry (LC MS) in body fluids. This acetylation is performed by the enzyme, spermine/spermidine N-acetyl transferase (SSAT). SSAT is observed in various cancers, including lung, breast, prostate, melanoma and gastrointestinal (GI) cancers. The analysis of SSAT messenger ribonucleic acid (mRNA) levels in tissue samples allows determination of cancer type.